Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
Open Access
- 1 April 2015
- journal article
- review article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 10, 2647-2652
Abstract
Chemotherapy, irradiation, and other agents are widely used to target the process of cell division in neoplastic cells. However, while these therapies are effective against most cancers, the high proliferative rate of the cells of the hematopoietic system that produce billions of blood cells needed daily throughout life is extremely sensitive to these agents, resulting in loss of blood cell populations, which can be life threatening. Neutropenia is the most serious hematologic toxicity of chemotherapy, which can result in patient morbidity and mortality due to opportunistic infection and often is the limiting factor in dose escalation or duration of chemotherapeutic administration. Neutropenic patients often require hospitalization and incur substantial medical costs associated with anti-infective therapy. Treatment of iatrogenic and congenic neutropenia was changed in the early 1990s with the introduction of filgrastim (Neupogen®) and pegfilgrastim (Neulasta®). With the expiration of patent lives of both of these drugs, biosimilars have begun to emerge. In this review, we will summarize the chemical characteristics, pharmacokinetics, safety and efficacy of lipegfilgrastim (Lonquex®), the first long-acting biosimilar filgrastim to receive regulatory approval and enter the marketplace.Keywords
This publication has 30 references indexed in Scilit:
- New G-CSF agonists for neutropenia therapyExpert Opinion on Investigational Drugs, 2013
- Costs Associated with Febrile Neutropenia in the USPharmacoEconomics, 2012
- Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective studyExperimental and Therapeutic Medicine, 2011
- Neutrophil kinetics in health and diseaseTrends in Immunology, 2010
- An Anniversary for Cancer ChemotherapyJAMA, 2006
- Differentiation and proliferation of hematopoietic stem cells.1993
- EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR ON HEMATOPOIETIC PROGENITOR CELLS IN CANCER-PATIENTS1988
- Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancerBritish Journal of Cancer, 1987
- Proliferative effects of purified granulocyte colony‐stimulating factor (G‐CSF) on normal mouse hemopoietic cellsJournal of Cellular Physiology, 1983
- NITROGEN MUSTARD THERAPYJAMA, 1946